From Pressure to Cancer: Unveiling the Integrin αV-YAP-CTGF Axis as a Therapeutic Target in Congestive Hepatopathy
Posted inCardiology Gastroenterology news

From Pressure to Cancer: Unveiling the Integrin αV-YAP-CTGF Axis as a Therapeutic Target in Congestive Hepatopathy

Researchers have identified a novel signaling pathway in liver sinusoidal endothelial cells (LSECs) that drives fibrosis and liver cancer in congestive hepatopathy. The study highlights the Integrin αV-YAP-CTGF axis as a critical mechanism and potential therapeutic target for patients with chronic hepatic congestion.
Decoding the Diabetic Heart: Five Unique Proteomic Markers Unveil Heart Failure Risk in Patients with Diabetes
Posted inCardiology Diabetes & Endocrinology news

Decoding the Diabetic Heart: Five Unique Proteomic Markers Unveil Heart Failure Risk in Patients with Diabetes

Researchers from the ARIC study have identified five specific proteomic markers that uniquely predict heart failure risk in individuals with diabetes. These findings, including four novel proteins, suggest distinct pathophysiological pathways for diabetic cardiomyopathy and offer new targets for precision screening and therapeutic intervention.
Beyond Statins: The Evolution and Clinical Impact of PCSK9 Inhibition in Cardiovascular Risk Management
Posted inCardiology Internal Medicine news

Beyond Statins: The Evolution and Clinical Impact of PCSK9 Inhibition in Cardiovascular Risk Management

This article explores the transformation of lipid management through PCSK9 inhibitors. From genetic discovery to landmark cardiovascular outcomes trials, we examine how monoclonal antibodies, RNA interference, and gene editing are redefining the boundaries of LDL-C reduction and patient care in atherosclerotic disease.
Levothyroxine in the Ageing Patient: Re-evaluating Cardiovascular Outcomes in Subclinical Hypothyroidism through the ACEL-UK-ETT Trial
Posted inCardiology Clinical Updates Diabetes & Endocrinology news

Levothyroxine in the Ageing Patient: Re-evaluating Cardiovascular Outcomes in Subclinical Hypothyroidism through the ACEL-UK-ETT Trial

This review analyzes the ACEL-UK-ETT emulated target trial, demonstrating that long-term levothyroxine therapy in older adults with subclinical hypothyroidism significantly reduces cardiovascular events and all-cause mortality without compromising bone health, provided age-specific TSH thresholds are utilized.